Eli Lilly and Company Stock Euronext Paris

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Euronext Paris 11:05:35 2019-10-29 am EDT 5-day change 1st Jan Change
98 EUR -1.01% Intraday chart for Eli Lilly and Company -.--% +2.08%
Sales 2024 * 42.99B 39.42B Sales 2025 * 52.8B 48.43B Capitalization 848B 778B
Net income 2024 * 11.93B 10.94B Net income 2025 * 16.68B 15.3B EV / Sales 2024 * 20.2 x
Net Debt 2024 * 20.24B 18.56B Net Debt 2025 * 16.14B 14.8B EV / Sales 2025 * 16.4 x
P/E ratio 2024 *
70.4 x
P/E ratio 2025 *
50.3 x
Employees -
Yield 2024 *
0.55%
Yield 2025 *
0.64%
Free-Float 99.8%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 56 95-12-31
President - -
Chief Tech/Sci/R&D Officer - 23-10-15
Members of the board TitleAgeSince
Director/Board Member 63 21-01-24
Director/Board Member 68 09-03-31
Director/Board Member 64 04-12-31
More insiders
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6 USD
Average target price
893.8 USD
Spread / Average Target
-5.08%
Consensus